The CEOs at Johnson & Johnson, Pfizer and Merck have big plans for future revenue even as they face difficult odds in the ...

Madrigal Pharmaceuticals is reiterated as a Strong Buy ahead of Q4 earnings, with a 12-month price target of $665, implying ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the best high growth high margin stocks to buy now. On January ...

Syndax Pharmaceuticals demonstrates strong commercial momentum with Revuforj and Niktimvo, driving notable revenue growth ...

XIANYANG CITY, SHAANXI PROVINCE, CHINA, January 21, 2026 /EINPresswire.com/ -- The pharmaceutical ingredients and ...

Indian pharma leaders emphasize shifting focus to high-value products and innovation for future growth and capability leadership.

Royalty Pharma reports Q1 2025 financials with 17% portfolio receipts growth, raising 2025 guidance to $2,975-$3,125 million. Royalty Pharma plc announced its financial results for the first quarter ...

At the heart of Delius Pharmaceuticals’ progress is a people-first approach. Today, the company is powered by a workforce of over 350 employees, and Shrivastava sees them as central to its success.

In the past week, West Pharmaceutical Services reported its 2025 results, with full-year sales rising to US$3.07 billion and net income edging up to US$493.7 million, while also issuing 2026 guidance ...

The market expects Jazz Pharmaceuticals (JAZZ) to deliver a year-over-year increase in earnings on higher revenues when it ...

West Pharmaceutical Services just sent investors $0.22 per share on February 4, 2026, marking the company’s latest quarterly dividend payment. For a business that’s quietly grown its payout for over a ...

Novartis CEO Vas Narasimhan received $32.4 million in total realized compensation in 2025, a marked increase compared to his take home pay in 2024. Narasimhan received 24.9 million Swiss Francs last ...